We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fresh from the biologic pipeline—2009.
- Authors
Sheridan, Cormac
- Abstract
The article highlights the developments in the U.S. biopharmaceutical industry in 2009. Particular focus is given on the approval of four monoclonal antibodies (mAbs) and H1N1 influenza vaccines in response to the swine flu pandemic. Additionally, it notes the approval of a recombinant protein produced in a transgenic animal. A discussion on the approved mAbs, including, Genentech's Herceptin for breast cancer, Centacor's Remicade for autoimmune diseases, Medarex's UltiMab, is detailed. Also tackled is the marketing of the said drugs.
- Subjects
UNITED States; BIOLOGICALS; PHARMACEUTICAL services; MONOCLONAL antibodies; H1N1 influenza; SWINE influenza; TRANSGENIC animals; VACCINATION
- Publication
Nature Biotechnology, 2010, Vol 28, Issue 4, p307
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0410-307